Onco Actu du 5 janvier 2016

	3.1 Tabac
Vaping really isn’t as harmful for your cells as smoking [New Scientist] Findings that vaping damages cells made headlines last week, but the real message of the study was the opposite of what was mostly reported.
UK regulators license BAT e-cigarette as quit-smoking medicine [Reuters] The decision to license BAT's e-Voke product means it can now be prescribed on the state-funded National Health Service for patients trying to give up smoking.
	3.4.1 Chimioprévention - aspirine
Regular Use of Aspirin May Help Thwart Prostate Cancer [Wall Street Journal] Researchers reported that men who took at least three aspirin tablets a week reduced their risk of developing or dying from advanced prostate cancer. The aspirin didn’t affect whether the men developed the disease to begin with, though.
	5. Traitements
The Drug Discoverer - More, better new drugs: five ways the system must change [The Institute of Cancer Research] Professor Paul Workman outlines five solutions to the challenge of the broken drug system of drug discovery and development, which is failing to deliver enough innovative new cancer drugs to those who need them.
You’ve been diagnosed with breast cancer. How soon do you need treatment? [Science-Based Medicine] Putting the results of these studies together suggests that it’s best to do surgery within about 60 days in patients not needing chemotherapy first, and that for patients with disease lacking the estrogen and progesterone receptor it’s best to start chemotherapy within 90 days of surgery.
	5.2.1 Pharma - Partenariats
Gustave Roussy Institute and Merus Partner for Novel Cancer Therapeutics Development [GEN] The agreement between the two organizations involves plans to collaborate on design and conduct of several studies involving Merus “Biclonics,” or therapeutic human bispecific antibody candidates, specifically Merus’ MCLA-128, a HER2xHER3 bispecific antibody candidate currently in Phase I/II clinical trials in Europe.
Merck KGaA, Darmstadt, Germany, Pfizer and Syndax Announce Collaboration to Evaluate Combination of Avelumab and Entinostat in Ovarian Cancer [Pfizer] Syndax will be responsible for conducting the Phase Ib/II clinical trial in ovarian cancer.
Baxalta inks deal to expand immuno-oncology business [Reuters] Drugmaker Baxalta Inc has signed a deal with privately held Symphogen under which the companies will develop immuno-oncology drugs to treat rare cancers.
	5.2.2 Pharma - Fusions & Acquisitions
Reports: $32bn Shire takeover of Baxalta close to done deal [Pharmafile] The deal may have failed to get over the line in 2015, but reports suggest the mega merger is to continue as a trend into the New Year, with Ireland’s Shire closer than ever to agreeing a deal for Baxalta, said to be worth $32 billion.
	5.2.3 Pharma - économie
Pfizer Versus BMS, Since 1989 [In the Pipeline] Pfizer has been a massively inefficient research organization. The disruptions from all those mergers are surely a big part of the problem, as is the sheer size of the company. Changing the entire course of R&D there, though, even if you knew just what to do, would disrupt things yet again. Pfizer is in a hole, folks.
	5.3 Traitements - FDA, EMA,...
2015: Another Strong Year for Patients in Need of New Drug Therapies [FDA Voice] In 2015, FDA’s Center for Drug Evaluation and Research (CDER) approved 45 novel new therapies – significantly more than the average of 28 we have approved during the previous nine years of this decade.
Drug approvals at 19-year high belie industry challenges [Reuters] 2015 was a good year for innovation in medicine with the U.S. Food and Drug Administration approving 45 novel drugs, four more than in 2014 and the most since the all-time record of 53 set in 1996. Across the Atlantic, the European Medicines Agency recommended 93 new products, including generics, up from 82 in 2014.
	5.9 AACR
Exelixis Announces Positive Results From Subgroup Analyses of the METEOR Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma to be Presented at ASCO 2016 Genitourinary Cancers Symposium [Exelixis] Bernard Escudier, M.D., chair of the Genitourinary Oncology Committee at the Institut Gustave Roussy (Villejuif, France) and an investigator on the METEOR trial, summarized the results during a press briefing in advance of the American Society of Clinical Oncology 2016 Genitourinary Cancers Symposium (ASCO GU), which is being held January 7-9, 2016 in San Francisco.
	5.9.4 AACR - poumon
Advancing Lung Cancer Research [CANCER RESEARCH Catalyst] The focus of this Fourth AACR-IASLC International Joint Conference is “Lung Cancer Translational Science from the Bench to the Clinic,” and attendees will hear about the most up-to-date advances across the spectrum of lung cancer research.
	6.1 Observation
Risk of heart damage follows some childhood cancer survivors [Reuters] The current study not only reinforces these risks, it also suggests that many childhood cancer survivors may encounter serious cardiac issues at a relatively young age when doctors may not routinely screen patients for heart disease.
	6.6 Publications
How to increase your Impact Factor by 40% [Brembs Blog] It continues to be an embarrassment for science that we rely on such a blatantly anti-scientific number for our hire-and-fire decisions and it spells trouble for the generation of scientists who are to come of this system.
	6.7 DMP, Big Data & applis
The unsung heroes of scientific software [Nature News & Comment] Creators of computer programs that underpin experiments don’t always get their due — so the website Depsy is trying to track the impact of research code.
The unsung heroes of scientific software [Nature News & Comment] Creators of computer programs that underpin experiments don’t always get their due — so the website Depsy is trying to track the impact of research code.